Organs age differently. To investigate the basis of organ-specific ageing we systematically compared at the tissue, stem cell and organoid level two organs representing ageing extremes, from accelera…
DNA analysis of thousands of tumors from NHS patients has found a ‘treasure trove’ of clues about the causes of cancer, with genetic mutations providing a personal history of the damage and repair processes each patient has been through.
In the biggest study of its kind, a team of scientists led by Professor Serena Nik-Zainal from Cambridge University Hospitals (CUH) and University of Cambridge, analyzed the complete genetic make-up or whole-genome sequences of more than 12,000 NHS cancer patients.
Because of the vast amount of data provided by whole genome sequencing, the researchers were able to detect patterns in the DNA of cancer—or ‘mutational signatures’—that provide clues about whether a patient has had a past exposure to environmental causes of cancer such as smoking or UV light, or has internal, cellular malfunctions.
In proof-of-concept experiments, Johns Hopkins Medicine scientists say they have successfully cultivated human muscle stem cells capable of renewing themselves and repairing muscle tissue damage in mice, potentially advancing efforts to treat muscle injuries and muscle-wasting disorders in people.
A report on the experiments was published April 7 in Cell Stem Cell.
To make the self-renewing stem cells, the scientists began with laboratory-grown human skin cells that were genetically reprogrammed to a more primitive state in which the cells have the potential to become almost any type of cell in the body. At this point, the cells are known as induced pluripotent stem (IPS) cells, and they are mixed with a solution of standard cell growth factors and nutrients that nudge them to differentiate into specific cell types.
UK researchers have developed a small, flexible, snake-like “magnetic tentacle robot” to navigate deep into the lungs.
Circa 2021 Synthetic silicon dna storage.
In research, the demand for DNA strands often outpaces supply. To help supply keep up, researchers may set aside traditional molecular cloning techniques and embrace polymerase chain reaction select PCR)-based techniques. Alternatively, researchers may perform gene synthesis, or the de novo chemical synthesis of DNA. Besides accelerating the creation of genetic sequences, gene synthesis avoids the need for template strands and simplifies procedures such as codon optimization and the fabrication of mutant sequences.
Although gene synthesis can be performed in house, many laboratories prefer to focus on their core competencies and outsource their gene synthesis projects to service providers, especially if sequences of over 1,000 base pairs are desired. Outsourcing also allows laboratories to take advantage of service providers’ economies of scale and quick turnaround times. Finally, service providers offer ease of use. Clients can go online, upload the desired sequences, choose the vector, get the price, and place the order. The entire process takes only a few minutes, and the genes can be delivered a few days later.
Researchers needing a few genes have a choice of several providers. But what if researchers need 10,000 genes? “We’re probably the only game in town,” suggests Emily Leproust, PhD, co-founder and CEO of Twist Bioscience.